Effects of rapamycin against paraquat-induced pulmonary fibrosis in mice

Journal of Zhejiang University: Science B

Volumn 16, Issue 1, 2015, Pages 52-61

  Shao, Xue ^a   Li, Meng ^a   Luo, Chong ^a   Wang, Ying ying ^a   Lu, Ying ying ^a   Feng, Shi ^a   Li, Heng ^a   Lang, Xia bing ^a   Wang, Yu cheng ^a   Lin, Chuan ^a   Shen, Xiu jin ^a   Zhou, Qin ^a   Jiang, Hong ^a   Chen, Jiang hua ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Methylprednisolone; Paraquat; Pulmonary fibrosis; Rapamycin; Transforming growth factor 1; Smooth muscle actin

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; EOSIN; HEMATOXYLIN; HYDROXYPROLINE; METHYLPREDNISOLONE; PARAQUAT; RAPAMYCIN; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA1; ACTIN; HERBICIDE; IMMUNOSUPPRESSIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTENT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EXPOSURE; DRUG INHIBITION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXCISION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS; LUNG FIBROSIS; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PARAQUAT POISONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; STAINING; SURVIVAL RATE; WEIGHT CHANGE; WEIGHT REDUCTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; LUNG; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; PULMONARY FIBROSIS; TREATMENT OUTCOME;

MUS;

ACTINS; ANIMALS; BODY WEIGHT; COLLAGEN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HERBICIDES; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; LUNG; MALE; METHYLPREDNISOLONE; MICE; MICE, INBRED C57BL; PARAQUAT; PROGNOSIS; PULMONARY FIBROSIS; SIROLIMUS; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME;

EID: 84920829083     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B1400229     Document Type: Article

References (34)

1. Baltazar, T., Dinis-Oliveira, R.J., Duarte, J.A., et al., 2013. Paraquat research: do recent advances in limiting its toxicity make its use safer? Br. J. Pharmacol., 168(1):44–45. [doi:10.1111/j.1476-5381.2012.02017.x]
2. Barrueto, F., Lee, C., Pajoumand, M., et al., 2008. Use of sirolimus in a case of severe paraquat poisoning. Clin. Toxicol., 46(8):778–779. [doi:10.1080/15563650701546219]
3. Biecker, E., de Gottardi, A., Neef, M., et al., 2005. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J. Pharmacol. Exp. Ther., 313(3):952–961. [doi:10.1124/jpet.104.079616]
4. Blanco-Ayala, T., Andérica-Romero, A.C., Pedraza-Chaverri, J., 2014. New insights into antioxidant strategies against paraquat toxicity. Free Radic. Res., 48(6):623–640. [doi:10.3109/10715762.2014.899694]
5. Bonegio, R.G., Fuhro, R., Wang, Z., et al., 2005. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J. Am. Soc. Nephrol., 16(7):2063–2072. [doi:10.1681/ASN.2004030180]
6. Chen, C.M., Su, B., Hsu, C.C., et al., 2002. Methylprednisolone does not enhance the surfactant effects on oxygenation and histology in paraquat-induced rat lung injury. Intensive Care Med., 28(8):1138–1144. [doi:10.1007/s00134-002-1350-2]
7. Chen, C.M., Chou, H.C., Hsu, H.H., et al., 2005. Transforming growth factor-β1 upregulation is -induced lung fibrosis. Toxicology, 216(2—3):181–187. [doi:10.1016/j.tox.2005.08.004]
8. Chen, G.H., Lin, J.L., Huang, Y.K., 2002. Combined methyl-prednisolone and dexamethasone therapy for paraquat poisoning. Crit. Care Med., 30(11):2584–2587. [doi:10.1097/00003246-200211000-00030]
9. Chen, J., Zeng, T., Zhao, X., et al., 2013. Docosahexaenoic acid (DHA) ameliorates paraquat-induced pulmonary fibrosis in rats possibly through up-regulation of Smad 7 and SnoN. Food Chem. Toxicol., 57:330–337. [doi:10.1016/j.fct.2013.03.045]
10. Chen, J.K., Chen, J., Neilson, E.G., et al., 2005. Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J. Am. Soc. Nephrol., 16(5): 1384–1391. [doi:10.1681/ASN.2004100894]
11. Chen, T., Nie, H., Gao, X., et al., 2014. Epithelial-mesenchymal transition involved in pulmonary fibrosis induced by multi-walled carbon nanotubes via TGF-β/Smad signaling pathway. Toxicol. Lett., 226(2):150–162. [doi:10.1016/j.toxlet.2014.02.004]
12. Chen, Y., Nie, Y.C., Luo, Y.L., et al., 2013. Protective effects of naringin against paraquat-induced acute lung injury and pulmonary fibrosis in mice. Food Chem. Toxicol., 58:133–140. [doi:10.1016/j.fct.2013.04.024]
13. Cui, Y., Robertson, J., Maharaj, S., et al., 2011. Oxidative stress contributes to the induction and persistence of TGF-β1 induced pulmonary fibrosis. Int. J. Biochem. Cell Biol., 43(8):1122–1133. [doi:10.1016/j.biocel.2011.04.005]
14. Cutroneo, K.R., White, S.L., Phan, S.H., et al., 2007. Therapies for bleomycin induced lung fibrosis through regulation of TGF-β1 induced collagen gene expression. J. Cell. Physiol., 211(3):585–589. [doi:10.1002/jcp.20972]
15. Geissler, E.K., Schlitt, H.J., 2010. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int., 78(11): 1075–1079. [doi:10.1038/ki.2010.324]
16. Hartford, C.M., Ratain, M.J., 2007. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin. Pharmacol. Ther., 82(4):381–388. [doi:10.1038/sj.clpt.6100317]
17. Helene, M., Lake-Bullock, V., Zhu, J., et al., 1999. T cell independence of bleomycin-induced pulmonary fibrosis. J. Leukoc. Biol., 65(2):187–195.
18. Kendall, R.T., Feghali-Bostwick, C.A., 2014. Fibroblasts in fibrosis: novel roles and mediators. Front. Pharmacol., 5:123. [doi:10.3389/fphar.2014.00123]
19. Korfhagen, T.R., Le Cras, T.D., Davidson, C.R., et al., 2009. Rapamycin prevents transforming growth factor-α-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol., 41(5):562–572. [doi:10.1165/rcmb.2008-0377OC]
20. Lee, R.A., Gabardi, S., 2012. Current trends in immune-suppressive therapies for renal transplant recipients. Am. J. Health Syst. Pharm., 69(22):1961–1975. [doi:10.2146/ajhp 110624]
21. Li, L.R., Sydenham, E., Chaudhary, B., et al., 2014. Glucocorticoid with cyclophosphamide for paraquatinduced lung fibrosis. Cochrane Database Syst. Rev., 8:CD008084. [doi:10.1002/14651858.CD008084.pub4]
22. Lloberas, N., Cruzado, J.M., Franquesa, M., et al., 2006. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J. Am. Soc. Nephrol., 17(5):1395–1404. [doi:10.1681/ASN.2005050549]
23. Lorenzen, J.M., Schonenberger, E., Hafer, C., et al., 2010. Failed rescue therapy with rapamycin after paraquat intoxication. Clin. Toxicol., 48(1):84–86. [doi:10.3109/15563650903376089]
24. Madala, S.K., Maxfield, M.D., Davidson, C.R., et al., 2011. Rapamycin regulates bleomycin-induced lung damage in SP-C-deficient mice. Pulm. Med., 2011:653524. [doi:10.1155/2011/653524]
25. Neef, M., Ledermann, M., Saegesser, H., et al., 2006. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J. Hepatol., 45(6):786–796. [doi:10.1016/j.jhep.2006.07.030]
26. Oka, H., Ishii, H., Iwata, A., et al., 2013. Inhibitory effects of pitavastatin on fibrogenic mediator production by human lung fibroblasts. Life Sci., 93(25–26):968–974. [doi:10.1016/j.lfs.2013.10.026]
27. Park, J.S., Park, K.H., Kim, H., et al., 2014. Effects of sivelestat treatment on acute lung injury in paraquat-intoxicated rats. Drug Chem. Toxicol., 37(1):114–120. [doi:10.3109/01480545.2013.834351]
28. Pham, P.T., Pham, P.C., Danovitch, G.M., et al., 2004. Sirolimus-associated pulmonary toxicity. Transplantation, 77(8): 1215–1220. [doi:10.1097/01.TP.0000118413.92211.B6]
29. Rocco, P.R., Souza, A.B., Faffe, D.S., et al., 2003. Effect of corticosteroid on lung parenchyma remodeling at an early phase of acute lung injury. Am. J. Respir. Crit. Care Med., 168(6):677–684. [doi:10.1164/rccm.200302-256OC]
30. Tulek, B., Kiyan, E., Toy, H., et al., 2011. Anti-inflammatory and anti-fibrotic effects of sirolimus on bleomycin-induced pulmonary fibrosis in rats. Clin. Invest. Med., 34(6):E341.
31. Vale, J.A., Meredith, T.J., Buckley, B.M., 1987. Paraquat poisoning: clinical features and immediate general management. Hum. Toxicol., 6(1):41–47. [doi:10.1177/09603 2718700600107]
32. Wang, J., Yu, Z.H., Zhou, Z.Y., et al., 2012. Inhibition of α-SMA by the ectodomain of FGFR2c attenuates lung fibrosis. Mol. Med., 18:992–1002. [doi:10.2119/molmed.2011.00425]
33. Wu, W.P., Lai, M.N., Lin, C.H., et al., 2014. Addition of immunosuppressive treatment to hemoperfusion is associated with improved survival after paraquat poisoning: a nationwide study. PLoS ONE, 9(1):e87568. [doi:10.1371/journal.pone.0087568]
34. Xu, X., Wan, X., Geng, J., et al., 2013. Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase. Exp. Biol. Med., 238(9):1082–1094. [doi:10.1177/1535370213498976]